The global market for Viral Inactivation was valued at US$781.3 Million in 2024 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 11.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and what they mean for your business.
The growth in the viral inactivation market is driven by several factors, including the expanding biologics pipeline, advancements in inactivation technologies, and increasing regulatory emphasis on biopharmaceutical safety. The adoption of single-use bioprocessing and automated viral clearance platforms is accelerating process efficiency while reducing contamination risks. Additionally, the rise of contract manufacturing is propelling demand for specialized viral inactivation services, creating new growth opportunities in the sector. The growing need for robust inactivation techniques in cell and gene therapy production is further fueling market expansion. As biopharmaceutical companies continue to invest in next-generation therapeutics, the demand for innovative and scalable viral inactivation solutions is expected to rise, ensuring sustained market growth.
Segments: Application (Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue/ Tissue Products, Cellular and Gene Therapy); Product (Kits & Reagents, Systems, Services).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Viral Inactivation Market - Key Trends & Drivers Summarized
Why Is Viral Inactivation Crucial for Biopharmaceutical Manufacturing?
Viral inactivation has become a cornerstone of biopharmaceutical production, ensuring that biologic drugs, including vaccines, monoclonal antibodies, and plasma-derived therapies, meet the highest safety standards. Regulatory agencies such as the FDA, EMA, and WHO have stringent guidelines mandating viral inactivation to prevent contamination and ensure patient safety. With the increasing reliance on biologics for the treatment of chronic diseases and autoimmune disorders, the demand for effective viral inactivation methods is soaring. Traditional methods such as solvent/detergent treatment, heat inactivation, and low pH inactivation continue to be widely used, while novel technologies, including UV-C irradiation and nanotechnology-based viral removal systems, are gaining traction to enhance the efficiency of bioprocessing workflows.What Innovations Are Shaping the Future of Viral Inactivation?
Technological innovations are revolutionizing viral inactivation techniques, improving process efficiency and ensuring compliance with evolving regulatory requirements. High-throughput and automated viral inactivation platforms are reducing process variability and improving scalability in large-scale biopharmaceutical production. The integration of AI and machine learning into bioprocessing workflows is optimizing inactivation parameters, enhancing reproducibility, and minimizing the risk of batch failures. Single-use bioprocessing systems are further driving advancements in viral inactivation, providing flexibility and cost-effectiveness while reducing cross-contamination risks. Additionally, advancements in filtration and chromatography techniques are enabling more precise and efficient viral removal without compromising product yield and quality.How Is the Biopharmaceutical Industry Driving Demand for Viral Inactivation?
The surge in monoclonal antibody and recombinant protein production has significantly boosted demand for viral inactivation solutions, as pharmaceutical companies seek to enhance product safety and accelerate regulatory approvals. The increasing development of cell and gene therapies is also reinforcing the need for advanced viral clearance and inactivation technologies to ensure the integrity of these highly sensitive therapies. Furthermore, the rise of contract development and manufacturing organizations (CDMOs) in biopharmaceutical production is increasing outsourcing of viral inactivation services, allowing biopharma firms to focus on drug development while ensuring stringent safety standards. With global vaccine development efforts intensifying, particularly in response to pandemics and emerging infectious diseases, viral inactivation remains a fundamental step in ensuring vaccine safety and efficacy.The growth in the viral inactivation market is driven by several factors, including the expanding biologics pipeline, advancements in inactivation technologies, and increasing regulatory emphasis on biopharmaceutical safety. The adoption of single-use bioprocessing and automated viral clearance platforms is accelerating process efficiency while reducing contamination risks. Additionally, the rise of contract manufacturing is propelling demand for specialized viral inactivation services, creating new growth opportunities in the sector. The growing need for robust inactivation techniques in cell and gene therapy production is further fueling market expansion. As biopharmaceutical companies continue to invest in next-generation therapeutics, the demand for innovative and scalable viral inactivation solutions is expected to rise, ensuring sustained market growth.
Report Scope
The report analyzes the Viral Inactivation market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.Segments: Application (Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue/ Tissue Products, Cellular and Gene Therapy); Product (Kits & Reagents, Systems, Services).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Kits & Reagents segment, which is expected to reach US$865.8 Million by 2030 with a CAGR of a 11.5%. The Systems segment is also set to grow at 12.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $214.8 Million in 2024, and China, forecasted to grow at an impressive 11.1% CAGR to reach $234.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Viral Inactivation Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Inactivation Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Viral Inactivation Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Merck KgaA, Parker Hannifin Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Viral Inactivation market report include:
- Charles River Laboratories International, Inc.
- Clean Cells Inc.
- Danaher Corporation
- Merck KgaA
- Parker Hannifin Corporation
- Rad Source Technologies, Inc.
- Sartorius AG
- SGS Group (SGS SA)
- Texcell, Inc.
- V.I.P.S. SA
- WuXi AppTec Group
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Charles River Laboratories International, Inc.
- Clean Cells Inc.
- Danaher Corporation
- Merck KgaA
- Parker Hannifin Corporation
- Rad Source Technologies, Inc.
- Sartorius AG
- SGS Group (SGS SA)
- Texcell, Inc.
- V.I.P.S. SA
- WuXi AppTec Group
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 173 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 781.3 Million |
| Forecasted Market Value ( USD | $ 1500 Million |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
